Appetite - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Appetite

The Experts below are selected from a list of 165597 Experts worldwide ranked by ideXlab platform

Appetite – Free Register to Access Experts & Abstracts

Bradley J. Christensen – One of the best experts on this subject based on the ideXlab platform.

  • Randomized Comparison of Megestrol Acetate Versus Dexamethasone Versus Fluoxymesterone for the Treatment of Cancer Anorexia/Cachexia
    Journal of Clinical Oncology, 1999
    Co-Authors: Charles Lawrence Loprinzi, John W Kugler, Jeff A. Sloan, James A Mailliard, James E Krook, Mary B. Wilwerding, Kendrith M Rowland, John K Camoriano, Paul J. Novotny, Bradley J. Christensen

    Abstract:

    PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve Appetites in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer anorexia/cachexia. PATIENTS AND METHODS: Patients suffering from cancer anorexia/cachexia were randomized to receive either dexamethasone 0.75 mg qid, megestrol acetate 800 mg orally every day, or fluoxymesterone 10 mg orally bid. Patients were observed at monthly intervals to evaluate weight changes and drug toxicity. Patients also completed questionnaires at baseline and at monthly intervals to evaluate Appetites and drug toxicities. RESULTS: Fluoxymesterone resulted in significantly less Appetite enhancement and did not have…

  • randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia cachexia
    Journal of Clinical Oncology, 1999
    Co-Authors: Charles Lawrence Loprinzi, John W Kugler, Jeff A. Sloan, James A Mailliard, James E Krook, Mary B. Wilwerding, Kendrith M Rowland, John K Camoriano, Paul J. Novotny, Bradley J. Christensen

    Abstract:

    PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve Appetites in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer anorexia/cachexia. PATIENTS AND METHODS: Patients suffering from cancer anorexia/cachexia were randomized to receive either dexamethasone 0.75 mg qid, megestrol acetate 800 mg orally every day, or fluoxymesterone 10 mg orally bid. Patients were observed at monthly intervals to evaluate weight changes and drug toxicity. Patients also completed questionnaires at baseline and at monthly intervals to evaluate Appetites and drug toxicities. RESULTS: Fluoxymesterone resulted in significantly less Appetite enhancement and did not have…

Charles Lawrence Loprinzi – One of the best experts on this subject based on the ideXlab platform.

  • Randomized Comparison of Megestrol Acetate Versus Dexamethasone Versus Fluoxymesterone for the Treatment of Cancer Anorexia/Cachexia
    Journal of Clinical Oncology, 1999
    Co-Authors: Charles Lawrence Loprinzi, John W Kugler, Jeff A. Sloan, James A Mailliard, James E Krook, Mary B. Wilwerding, Kendrith M Rowland, John K Camoriano, Paul J. Novotny, Bradley J. Christensen

    Abstract:

    PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve Appetites in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer anorexia/cachexia. PATIENTS AND METHODS: Patients suffering from cancer anorexia/cachexia were randomized to receive either dexamethasone 0.75 mg qid, megestrol acetate 800 mg orally every day, or fluoxymesterone 10 mg orally bid. Patients were observed at monthly intervals to evaluate weight changes and drug toxicity. Patients also completed questionnaires at baseline and at monthly intervals to evaluate Appetites and drug toxicities. RESULTS: Fluoxymesterone resulted in significantly less Appetite enhancement and did not have…

  • randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia cachexia
    Journal of Clinical Oncology, 1999
    Co-Authors: Charles Lawrence Loprinzi, John W Kugler, Jeff A. Sloan, James A Mailliard, James E Krook, Mary B. Wilwerding, Kendrith M Rowland, John K Camoriano, Paul J. Novotny, Bradley J. Christensen

    Abstract:

    PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve Appetites in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer anorexia/cachexia. PATIENTS AND METHODS: Patients suffering from cancer anorexia/cachexia were randomized to receive either dexamethasone 0.75 mg qid, megestrol acetate 800 mg orally every day, or fluoxymesterone 10 mg orally bid. Patients were observed at monthly intervals to evaluate weight changes and drug toxicity. Patients also completed questionnaires at baseline and at monthly intervals to evaluate Appetites and drug toxicities. RESULTS: Fluoxymesterone resulted in significantly less Appetite enhancement and did not have…

James A Mailliard – One of the best experts on this subject based on the ideXlab platform.

  • Randomized Comparison of Megestrol Acetate Versus Dexamethasone Versus Fluoxymesterone for the Treatment of Cancer Anorexia/Cachexia
    Journal of Clinical Oncology, 1999
    Co-Authors: Charles Lawrence Loprinzi, John W Kugler, Jeff A. Sloan, James A Mailliard, James E Krook, Mary B. Wilwerding, Kendrith M Rowland, John K Camoriano, Paul J. Novotny, Bradley J. Christensen

    Abstract:

    PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve Appetites in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer anorexia/cachexia. PATIENTS AND METHODS: Patients suffering from cancer anorexia/cachexia were randomized to receive either dexamethasone 0.75 mg qid, megestrol acetate 800 mg orally every day, or fluoxymesterone 10 mg orally bid. Patients were observed at monthly intervals to evaluate weight changes and drug toxicity. Patients also completed questionnaires at baseline and at monthly intervals to evaluate Appetites and drug toxicities. RESULTS: Fluoxymesterone resulted in significantly less Appetite enhancement and did not have…

  • randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia cachexia
    Journal of Clinical Oncology, 1999
    Co-Authors: Charles Lawrence Loprinzi, John W Kugler, Jeff A. Sloan, James A Mailliard, James E Krook, Mary B. Wilwerding, Kendrith M Rowland, John K Camoriano, Paul J. Novotny, Bradley J. Christensen

    Abstract:

    PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve Appetites in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer anorexia/cachexia. PATIENTS AND METHODS: Patients suffering from cancer anorexia/cachexia were randomized to receive either dexamethasone 0.75 mg qid, megestrol acetate 800 mg orally every day, or fluoxymesterone 10 mg orally bid. Patients were observed at monthly intervals to evaluate weight changes and drug toxicity. Patients also completed questionnaires at baseline and at monthly intervals to evaluate Appetites and drug toxicities. RESULTS: Fluoxymesterone resulted in significantly less Appetite enhancement and did not have…